TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12002664

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate ophthalmic gel-forming solution QD
Number of subjects: 133

Group type: COMPARATOR
Intervention: 0.5% levobunolol hydrochloride BID
Number of subjects: 133
Study: 9950291

Group type: EXPERIMENTAL
Intervention: Truncated area (AUCt) for amiodarone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Truncated area (AUCt) for danazol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Area to the last quantifiable time point (AUC(0-T)) for amiodarone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Area to the last quantifiable time point (AUC(0-T)) for danazol
Number of subjects: 24
Study: 7791837

Group type: EXPERIMENTAL
Intervention: Aggressive transfusion regimen (designed to decrease hemoglobin S level to less than 30 percent)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Conservative transfusion regimen (designed to increase hemoglobin level to 10 g per deciliter)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aggressive transfusion regimen
Number of subjects: 604

Group type: COMPARATOR
Intervention: Conservative transfusion regimen
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Both aggressive and conservative transfusion regimens
Number of subjects: 604
Study: 2189906

Group type: EXPERIMENTAL
Intervention: R 68 151 2% ointment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 88
Study: 74662

Group type: EXPERIMENTAL
Intervention: gamma-globulin concentrate as adjunctive therapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: standard immunosuppressive regimen (control group)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: gamma-globulin concentrate
Number of subjects: 195
Study: 31313270

Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (extended half-life factor VIII replacement therapy) infused once every 7 days, once every 5 days, or twice weekly
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BAY 94-9027
Number of subjects: 16
Study: 28656968

Group type: EXPERIMENTAL
Intervention: Home jejunostomy feeding (n=18)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care without feeding (n=23)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rescue feeding (n=6)
Number of subjects: 41
Study: 27465608

Group type: EXPERIMENTAL
Intervention: Immersion in thermoneutral water (ITW) for 45-60 min, 4 times a week for 4 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Immersion in thermoneutral water (ITW) for 45-60 min, 4 times a week for 4 weeks, then reduced to 1 bath a week for 20 weeks (Bath1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Immersion in thermoneutral water (ITW) for 45-60 min, 4 times a week for 4 weeks (Bath2)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group instructed to relax for 45-60 min, 4 times a week for 24 weeks using a relaxation CD
Number of subjects: 59
Study: 24774590

Group type: EXPERIMENTAL
Intervention: Conventional management of heart failure and an individualized nutritional intervention (optimization of diet, specific recommendations, and nutritional supplements if necessary)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional management of heart failure
Number of subjects: 182
Study: 22395092

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 319

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 319

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 319
Study: 20882526

Group type: EXPERIMENTAL
Intervention: Prophylaxis with ciprofloxacin, orally, and vancomycin, intravenously
Number of subjects: 157

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 157
Study: 18569896

Group type: EXPERIMENTAL
Intervention: Maintaining balance coping strategy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Avoidance coping strategy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Focusing on caregiving coping strategy
Number of subjects: 115
Study: 15748694

Group type: EXPERIMENTAL
Intervention: Ultrasound self-therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 8
Study: 12452946

Group type: EXPERIMENTAL
Intervention: Higher dose gum (900 mg CaCO3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lower dose gum (600 mg CaCO3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chewable antacid tablets (1000 mg CaCO3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active chewable antacid and gums
Number of subjects: 24
Study: 9872843

Group type: EXPERIMENTAL
Intervention: Nocturnal asthma (NA) group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alveolar tissue CD4+ cells
Number of subjects: 21
Study: 7535996

Group type: EXPERIMENTAL
Intervention: 200‐mL boluses of a 6% hydroxyethyl starch solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard practices (Control)
Number of subjects: 60
Study: 1561645

Group type: EXPERIMENTAL
Intervention: 20% albumin plus crystalloids
Number of subjects: 300

Group type: COMPARATOR
Intervention: Crystalloids (control group)
Number of subjects: 300
Study: 4054196

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30759887

Group type: EXPERIMENTAL
Intervention: Fe‐Beans
Number of subjects: 574

Group type: COMPARATOR
Intervention: Control‐Beans
Number of subjects: 574
Study: 28756042

Group type: EXPERIMENTAL
Intervention: Continue Patch
Number of subjects: 701

Group type: COMPARATOR
Intervention: Discontinue Patch
Number of subjects: 701
Study: 27117056

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) continuation as a single agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: No BEV (treatment holidays)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) continuation
Number of subjects: 0
Study: 24632316

Group type: EXPERIMENTAL
Intervention: PBMNC + PNS
Number of subjects: 52

Group type: COMPARATOR
Intervention: PBMNC
Number of subjects: 52
Study: 23403336

Group type: EXPERIMENTAL
Intervention: Maxillary advancement only
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined with mandibular setback
Number of subjects: 50
Study: 21207496

Group type: EXPERIMENTAL
Intervention: Medicinal leech therapy (MLT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Venous catheterization (VC)
Number of subjects: 56
Study: 19525451

Group type: EXPERIMENTAL
Intervention: CT plus (18)F‐FDG PET
Number of subjects: 150

Group type: COMPARATOR
Intervention: CT only
Number of subjects: 150
Study: 17694485

Group type: EXPERIMENTAL
Intervention: Rational Rehabilitation
Number of subjects: 19
Study: 15468016

Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wellness education (WE) program
Number of subjects: 28
Study: 11789299

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 67% omega-3 fatty acids (185 mg EPA and 465 mg DHA) in a spread form, 7 grams daily for 12 weeks.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Olive oil spread (placebo)
Number of subjects: 52
Study: 9541192

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 7744898

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 184

Group type: COMPARATOR
Intervention: Intramuscular injections
Number of subjects: 184
Study: 2143300

Group type: EXPERIMENTAL
Intervention: Akne-Mycyna (1% erythromycin), applied twice daily for at least 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Akne-Mycyna (1% erythromycin)
Number of subjects: 30
Study: 6112131

Group type: EXPERIMENTAL
Intervention: Benzodiazepine anxiolytics
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Psychostimulants (amphetamine type)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31765987

Group type: EXPERIMENTAL
Intervention: S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) regimen
Number of subjects: 73
Study: 30149997

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (100Sn kVp, 70 mAs)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard-dose CT (110 kVp, 50 mAs)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard-dose CT
Number of subjects: 210
Study: 28912631

Group type: EXPERIMENTAL
Intervention: Shoulder treatment plus cervicothoracic spinal thrust/non-thrust
Number of subjects: 18

Group type: COMPARATOR
Intervention: Shoulder treatment-only group
Number of subjects: 18
Study: 26371134

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Anastrozole 1 mg
Number of subjects: 205
Study: 23681913

Group type: EXPERIMENTAL
Intervention: Slow breathing (6 breaths/min)
Number of subjects: 16
Study: 19451435

Group type: EXPERIMENTAL
Intervention: Imatinib (IM) 400 mg daily
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Imatinib (IM) 600 mg daily
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Imatinib (IM) with KIT exon 11 mutations
Number of subjects: 73
Study: 17968921

Group type: EXPERIMENTAL
Intervention: High molecular weight cross-linked hylan
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Non-cross-linked medium molecular weight HA of avian origin
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Non-cross-linked low molecular weight HA of bacterial origin
Number of subjects: 660

Group type: COMPARATOR
Intervention: Hylan
Number of subjects: 660
Study: 15084900

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pleasant and unpleasant slides
Number of subjects: 61
Study: 11273587

Group type: EXPERIMENTAL
Intervention: High-dose leucovorin (175 mg) with fluorouracil (370 mg/m2)
Number of subjects: 4927

Group type: COMPARATOR
Intervention: Low-dose leucovorin (25 mg) with fluorouracil (370 mg/m2)
Number of subjects: 4927

Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg) with fluorouracil and leucovorin
Number of subjects: 4927

Group type: COMPARATOR
Intervention: Placebo with fluorouracil and leucovorin
Number of subjects: 4927

Group type: EXPERIMENTAL
Intervention: Weekly treatment regimen
Number of subjects: 4927

Group type: COMPARATOR
Intervention: Monthly treatment regimen
Number of subjects: 4927
Study: 9612276

Group type: EXPERIMENTAL
Intervention: 0.5 IDU.kg‐1.h‐1 CCK
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.0 IDU.kg‐1.h‐1 CCK
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 7834324

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg/day for 21 days
Number of subjects: 30
Study: 2024862

Group type: EXPERIMENTAL
Intervention: Aerosol pentamidine, 60 mg per dose, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Aerosol pentamidine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 7416269

Group type: EXPERIMENTAL
Intervention: Hemodialysis, twice weekly for 10 weeks
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham dialysis, twice weekly for 10 weeks
Number of subjects: 4
Study: 31112026

Group type: EXPERIMENTAL
Intervention: Non-adenocarcinoma pancreatic cancer (NACPC)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Adenocarcinoma pancreatic cancer (ACPC)
Number of subjects: 441
Study: 28866763

Group type: EXPERIMENTAL
Intervention: Standard treatment (StnTx: two servings milk and milk products/day; meet PA guidelines plus weight-bearing PA three times/week)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Modified treatment (ModTx: four servings milk and milk products/day; meet PA guidelines plus daily weight-bearing PA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (Ctrl; no intervention)
Number of subjects: 78
Study: 26522641

Group type: EXPERIMENTAL
Intervention: Simulated infobutton linked to UpToDate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional Internet resources
Number of subjects: 44
Study: 23578004

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg three times a day for 5 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 21826205

Group type: EXPERIMENTAL
Intervention: Skin conductance responses (SCRs) during observation of pain in others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin conductance responses (SCRs) during self pain
Number of subjects: 0
Study: 19728603

Group type: EXPERIMENTAL
Intervention: Microsurgery lumbar discectomy (MSLD)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Traditional open discectomy by fenestration
Number of subjects: 230
Study: 16939522

Group type: EXPERIMENTAL
Intervention: Novel matrix transdermal delivery system of fentanyl
Number of subjects: 24

Group type: COMPARATOR
Intervention: Durogesic reservoir formulation
Number of subjects: 24
Study: 14741301

Group type: EXPERIMENTAL
Intervention: Mechanical perturbation applied to the right foot during paced walking
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mechanical perturbation applied laterally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mechanical perturbation applied medially
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mechanical perturbation
Number of subjects: 12
Study: 11485582

Group type: EXPERIMENTAL
Intervention: Topical application of butylcyanoacrylate
Number of subjects: 101

Group type: COMPARATOR
Intervention: Polypropylene sutures
Number of subjects: 101
Study: 9684388

Group type: EXPERIMENTAL
Intervention: Marijuana users
Number of subjects: 107

Group type: COMPARATOR
Intervention: Non-marijuana users
Number of subjects: 107
Study: 7603076

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg o.d.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg o.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 3250868

Group type: EXPERIMENTAL
Intervention: 200 mg ferrous sulphate
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 5 mg riboflavin and 150 mg ascorbic acid
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30324561

Group type: EXPERIMENTAL
Intervention: Composite resin (Z250, 3M ESPE)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Resin Modified Glass Ionomer Cement (Vitremer, 3M ESPE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both materials (Z250 and Vitremer)
Number of subjects: 55
Study: 28501361

Group type: EXPERIMENTAL
Intervention: Three cycles of IUI + COH (n = 101)
Number of subjects: 207

Group type: COMPARATOR
Intervention: One cycle of IVF (n = 106)
Number of subjects: 207
Study: 25646352

Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy for Smoking Cessation (PPT-S)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 66
Study: 23909402

Group type: EXPERIMENTAL
Intervention: L-carnitine (900 mg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 20962342

Group type: EXPERIMENTAL
Intervention: Dilute diesel exhaust (particle concentration 300 μg/m³)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 52
Study: 18704484

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (1.7 MJ day(‐1) high-protein supplement composed of 50% valine, 35% leucine, and 15% isoleucine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (standard diet of 14.5 MJ day(‐1) with 58% carbohydrate, 30% fat, and 12% protein)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (BCAA and Control)
Number of subjects: 12
Study: 17039422

Group type: EXPERIMENTAL
Intervention: metformin plus liraglutide
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 144
Study: 14573827

Group type: EXPERIMENTAL
Intervention: Home sampling
Number of subjects: 962

Group type: COMPARATOR
Intervention: Office sampling
Number of subjects: 962
Study: 16948207

Group type: EXPERIMENTAL
Intervention: Elastic support bandage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Collar and cuff sling
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Elevation on two pillows
Number of subjects: 90
Study: 8836219

Group type: EXPERIMENTAL
Intervention: Express saccade makers (ES makers)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 1486457

Group type: EXPERIMENTAL
Intervention: Dopaminergic therapy (levodopa, bromocriptine)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs
Number of subjects: 82
Study: 6376294

Group type: EXPERIMENTAL
Intervention: External pneumatic calf compression (EPC) applied perioperatively
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (no EPC)
Number of subjects: 194
Study: 30182287

Group type: EXPERIMENTAL
Intervention: Cross-education (strength training of the non-operated leg during weeks 1-12 after surgery)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard care (both groups received this after ACL reconstruction)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Non-injured leg (hop distance)
Number of subjects: 43
Study: 29631203

Group type: EXPERIMENTAL
Intervention: Active rTMS (55 trains, 18 Hz, 120% resting motor threshold intensity)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 43
Study: 26422745

Group type: EXPERIMENTAL
Intervention: SSE intervention
Number of subjects: 494

Group type: COMPARATOR
Intervention: Customary care (control)
Number of subjects: 494
Study: 24530488

Group type: EXPERIMENTAL
Intervention: NOURISH+MI (Motivational Interviewing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NOURISH(+)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22652461

Group type: EXPERIMENTAL
Intervention: Neuromonitoring during thyroid surgery (group A)
Number of subjects: 259

Group type: COMPARATOR
Intervention: No neuromonitoring during thyroid surgery (control group B)
Number of subjects: 259
Study: 20708714

Group type: EXPERIMENTAL
Intervention: Micronutrient and antioxidant preparation
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard multivitamins (identical appearing recommended daily allowance multivitamin and mineral preparation)
Number of subjects: 218
Study: 17408055

Group type: EXPERIMENTAL
Intervention: Nicardipine 15 microg/kg IV 30 s after induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 40
Study: 16280697

Group type: EXPERIMENTAL
Intervention: HAART plus subcutaneous IL-2
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HAART plus intravenous IL-2
Number of subjects: 148

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 148
Study: 12118904

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of enalapril (10 mg/day) and eprosartan (300 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10468077

Group type: EXPERIMENTAL
Intervention: Chewed buffered aspirin tablet (325 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Swallowed whole buffered aspirin tablet (325 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buffered aspirin solution (Alka Seltzer)
Number of subjects: 12
Study: 7786212

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac eye drops
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1% prednisolone eye drops
Number of subjects: 52
Study: 2260502

Group type: EXPERIMENTAL
Intervention: Intralesional Hu‐IFN‐alpha (10^5 to 2 x 10^5 IU)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intralesional Hu‐IFN‐alpha
Number of subjects: 9
Study: 462483

Group type: EXPERIMENTAL
Intervention: Single test dose of irradiation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fractionated test dose of irradiation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study: 31493216

Group type: EXPERIMENTAL
Intervention: rhAT-gamma (72 IU/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: pAT (60 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhAT-gamma (60 IU/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhAT-gamma
Number of subjects: 0
Study: 28777690

Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Nomograms for progression-free survival (PFS)
Number of subjects: 493
Study: 25736134

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin calcium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin calcium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 60 mg atorvastatin calcium
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (20 mg atorvastatin calcium)
Number of subjects: 120
Study: 23931541

Group type: EXPERIMENTAL
Intervention: High physician-expressed uncertainty (female physician)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Low physician-expressed uncertainty (female physician)
Number of subjects: 189

Group type: COMPARATOR
Intervention: High physician-expressed uncertainty (male physician)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Low physician-expressed uncertainty (male physician)
Number of subjects: 189
Study: 20974459

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 427

Group type: COMPARATOR
Intervention: Overweight/obese status (BMI ≥25.0)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 427

Group type: COMPARATOR
Intervention: Pregnancy-induced hypertension
Number of subjects: 427

Group type: COMPARATOR
Intervention: Latinas (BMI by race interaction)
Number of subjects: 427
Study: 19894299

Group type: EXPERIMENTAL
Intervention: Amantadine sulfate (PK-Merz)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 40